Insights
Newsletters
All Eyes on AI: Regulatory, Litigation, and Transactional Developments – Q1 2026
Wilson Sonsini is pleased to present the next edition of All Eyes on AI: Regulatory, Litigation, and Transactional Developments, which closely follows the evolving regulatory landscape for artificial intelligence (AI) in the U.S., new EU regulations for AI, international developments, litigation, recent deal highlights, firm publications, and other AI and machine learning highlights.
Newsletters
The Life Sciences Report – June 2026
This latest edition features articles on accelerating new therapies under the new FDA administration, cash-pay healthcare companies possibly facing kickback and fee-splitting risk under federal and state laws, building in-house legal teams for biotech, digital health, and medical devices companies, and life sciences venture financings for firm clients across 1H2025 and 2H2025.
Newsletters
The Entrepreneurs Report – Q1 2026
Wilson Sonsini is pleased to present the Q1 2026 edition of The Entrepreneurs Report. We’ve compiled a range of data on venture, convertible note, and SAFE financing transactions in which the firm was involved during the first quarter, with the objective of identifying relevant trends in activity and valuation levels for the U.S. venture capital industry in general.
All Results
Client Highlights
7.01.26
Wilson Sonsini Advises Kai Health on $4.8 Million Seed Round
On June 29, 2026, Kai Health, an AI-powered performance improvement platform for emergency medicine, announced a $4.8 million seed round led by Distributed Ventures. Wilson Sonsini Goodrich & Rosati advised Kai Health on the transaction.
Client Highlights
7.01.26
Wilson Sonsini Advises yes& on $3 Million Pre-Seed Financing
On June 23, 2026, yes&, a remix-native AI creative community platform, announced that it has raised $3 million in pre-seed funding, led by Accel with support from Parable. Wilson Sonsini Goodrich & Rosati advised yes& on the transaction.
Client Highlights
6.30.26
Wilson Sonsini Advises Cognite, Major Shareholders on $3.1 Billion Sale to Schneider Electric
On June 30, 2026, Aker ASA (Aker) and the other shareholders of Cognite announced that they have entered into an agreement to sell 100 percent of the shares in Cognite Holding B.V. (Cognite) to Schneider Electric based on an enterprise value of US$3.1 billion. Wilson Sonsini Goodrich & Rosati’s cross-border tech M&A team advised Cognite and its major shareholders, including Aker, TCV, and Accel, on the transaction.
Client Highlights
6.30.26
Wilson Sonsini Advises Rocket Lab on $8 Billion Acquisition of Iridium
On June 29, 2026, Rocket Lab Corporation, a global leader in launch and space systems, and Iridium Communications, a leading provider of global voice, data and positioning, navigation, and timing satellite services, announced they have entered into a definitive agreement under which Rocket Lab will acquire Iridium. Rocket Lab will acquire all the outstanding shares of Iridium common stock for $54 per share in a cash and stock transaction. This represents an enterprise value for Iridium of approximately $8 billion. Wilson Sonsini Goodrich & Rosati is advising Rocket Lab on the transaction.
Alerts
6.26.26
FTC Conditions Aurobindo’s Acquisition of Lannett on Divestiture of Four Generic Drugs
On June 18, 2026, the Federal Trade Commission (FTC) announced that it would allow Aurobindo Pharma Limited’s approximately $250 million acquisition of Lannett Company, Inc. to proceed, subject to a proposed consent order requiring Aurobindo to divest four overlapping generic pharmaceutical products to Quagen Pharmaceuticals, LLC. The Commission voted 2-0 to issue an administrative complaint and accept the consent agreement for a 30-day public comment period.
News Articles
6.26.26
Wilson Sonsini Attorneys Named to 2026 Lawdragon 500 Leading Energy Lawyers Guide
On June 26, 2026, Lawdragon released the newest edition of its Lawdragon 500 Leading Energy Lawyers guide, recognizing attorneys in the oil and gas sector, experts in infrastructure and project development, energy litigators, and dealmakers who are reinvigorating their focus on traditional energy, among others. Wilson Sonsini partners Matthew Bogdan, Matthew Christiansen, Nic Gladd, and Jason Slagle were listed in this year’s guide.
Client Highlights
6.25.26
Wilson Sonsini Advises Sail Research on $80 Million Series A
On June 25, 2026, Sail Research, an infrastructure company purpose-built for long-horizon AI agents, announced it has raised $80 million in seed and Series A funding at a $450 million valuation. The Series A was led by Kleiner Perkins, and the seed round was led by Sequoia. Other participating investors included Redpoint Ventures, Theory Ventures, Vine Ventures, CRV, A*, and Abstract Ventures, in addition to angel investors, including John Hennessy, chairman of Alphabet Inc., Lip-Bu Tan, CEO of Intel, and Tri Dao, Chief Scientist at Together AI. Wilson Sonsini Goodrich & Rosati advised Sail Research on the transaction.
News Articles
6.25.26
Wilson Sonsini Receives NLADA 2026 Beacon of Justice Award
On June 25, 2026, the National Legal Aid & Defender Association (NLADA) announced that Wilson Sonsini Goodrich & Rosati is one of 33 law firms that will be honored with the 2026 Beacon of Justice Award. The awards honor members of the pro bono legal community who are tireless advocates for equal justice. Wilson Sonsini is one of approximately seven law firms to receive the Beacon of Justice Award for six consecutive years.
Client Highlights
6.24.26
Firm Advises Underwriters on Legend Biotech’s Public Offering
On June 17, 2026, Legend Biotech Corporation, a global leader in cell therapy, announced the pricing of an underwritten public offering of 7,700,000 American Depositary Shares (ADSs), each representing two ordinary shares of the company, at a public offering price of $29.35 per ADS. In addition, Legend Biotech has granted the underwriters a 30-day option to purchase up to an additional 1,155,000 ADSs at the public offering price, less underwriting discounts and commissions. The gross proceeds to Legend Biotech from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Legend Biotech, were approximately $226 million, excluding any proceeds from the exercise of the underwriters’ option to purchase additional ADSs. Wilson Sonsini Goodrich & Rosati advised the underwriters on the transaction.
Client Highlights
6.24.26
Wilson Sonsini Advises Assort Health on $120 Million Series C
On June 24, 2026, Assort Health, the most widely used AI agents platform for the patient journey, announced a $120 million Series C led by Menlo Ventures at a valuation of $1.2 billion. Assort has now raised more than $222 million to become the standard for healthcare organizations wanting to transform the patient journey with AI. Wilson Sonsini Goodrich & Rosati advised Assort on the transaction.
In addition to Menlo Ventures, investors participating in the Series C financing include Lightspeed Venture Partners, Felicis, First Round Capital, Chemistry, Joe Montana, Tau Ventures, and Quiet Capital.
What began as the first voice AI agent to schedule a specialty appointment is now a platform spanning scheduling, intake forms, referrals, document processing, medication refills, real time eligibility, lab requests, and payments. That expansion has been powered by more than 190 million patient interactions, 62,000 care protocols, and 1.6 million decision pathways, creating the largest proprietary specialty dataset in healthcare.
The Wilson Sonsini team that advised Assort on the financing included Lang Liu, Alex Youssef, Madisyn Klein, and Nara Jo.
For more information, please see Assort’s blog post.
In addition to Menlo Ventures, investors participating in the Series C financing include Lightspeed Venture Partners, Felicis, First Round Capital, Chemistry, Joe Montana, Tau Ventures, and Quiet Capital.
What began as the first voice AI agent to schedule a specialty appointment is now a platform spanning scheduling, intake forms, referrals, document processing, medication refills, real time eligibility, lab requests, and payments. That expansion has been powered by more than 190 million patient interactions, 62,000 care protocols, and 1.6 million decision pathways, creating the largest proprietary specialty dataset in healthcare.
The Wilson Sonsini team that advised Assort on the financing included Lang Liu, Alex Youssef, Madisyn Klein, and Nara Jo.
For more information, please see Assort’s blog post.